CIBMTR Reporting Implementation Guide
0.1.6 - Trial Use 1

CIBMTR Reporting Implementation Guide - Local Development build (v0.1.6). See the Directory of published versions

: SNOMED Myelodysplastic Diseases - TTL Representation

Active as of 2023-05-05

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:ValueSet ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "snomed-myelodysplastic-diseases-vs"] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li>Include codes from <a href=\"http://www.snomed.org/\"><code>http://snomed.info/sct</code></a> where concept  is-a  109995007 (Myelodysplastic syndrome (clinical))</li></ul></div>"
  ] ; # 
  fhir:url [ fhir:v "http://fhir.nmdp.org/ig/cibmtr-reporting/ValueSet/snomed-myelodysplastic-diseases-vs"^^xsd:anyURI] ; # 
  fhir:version [ fhir:v "0.1.6"] ; # 
  fhir:name [ fhir:v "SNOMEDMyelodysplasticDiseasesVS"] ; # 
  fhir:title [ fhir:v "SNOMED Myelodysplastic Diseases"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:experimental [ fhir:v "true"^^xsd:boolean] ; # 
  fhir:date [ fhir:v "2023-05-05T10:07:01-05:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "The Medical College of Wisconsin, Inc. and the National Marrow Donor Program"] ; # 
  fhir:contact ( [
fhir:name [ fhir:v "The Medical College of Wisconsin, Inc. and the National Marrow Donor Program" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://www.cibmtr.org" ]     ] )
  ] [
fhir:name [ fhir:v "Bob Milius" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "bmilius@nmdp.org" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia (abnormal growth or development leading to an alteration in size, shape, and organization of the cell) in one or more of the major myeloid cell lines (WBC, RBC, and/or platelets), ineffective hematopoiesis, and an increased risk of developing acute myelogenous leukemia (AML). MDS occurs primarily in older adults, with a median age of 70 years. The majority of recipients present with symptoms related to cytopenias. Most recipients present with anemia requiring RBC transfusions."] ; # 
  fhir:compose [
    ( fhir:include [
fhir:system [ fhir:v "http://snomed.info/sct"^^xsd:anyURI ] ;
      ( fhir:filter [
fhir:property [ fhir:v "concept" ] ;
fhir:op [ fhir:v "is-a" ] ;
fhir:value [ fhir:v "109995007" ]       ] )     ] )
  ] . #